HDAC11 and cancer: Its overexpression in various cancers, including hepatocellular, ovarian, myeloma, lymphoma, and breast cancers (Gong et al., 2019; Huang et al., 2018; Liu et al., 2020; Yue et al., 2020; Zhou et al., 2018), has suggested HDAC11 is an epigenetic regulator in human cancers.